Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 15/20 | 0.61 |
| ▸ | OPRL1 | P41146 | 14/20 | 0.61 |
| ▸ | OPRK1 | P41145 | 14/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1862708 | 0.84 | OPRM1 (0.67) | OPRM1OPRL1OPRK1CTSSHTR2A | |
| SCHEMBL181682 | 0.77 | OPRM1 (1.00) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL14543172 | 0.76 | OPRM1 (0.71) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL1860312 | 0.76 | OPRM1 (0.74) | OPRM1OPRL1OPRK1HTR2AHTR7 | |
| SCHEMBL15861172 | 0.73 | OPRM1 (0.51) | OPRM1OPRL1OPRK1 | |
| SCHEMBL15861190 | 0.73 | OPRM1 (0.49) | OPRM1OPRL1OPRK1 | |
| SCHEMBL10316251 | 0.73 | OPRM1 (0.69) | OPRM1OPRL1OPRK1 | |
| SCHEMBL1859464 | 0.73 | OPRL1 (0.86) | OPRM1OPRL1OPRK1CTSSHTR2A | |
| SCHEMBL15847796 | 0.73 | OPRL1 (0.46) | OPRM1OPRL1 | |
| SCHEMBL15861290 | 0.72 | OPRL1 (0.44) | OPRM1OPRL1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | SUNOVION PHARMACEUTICALS INC. | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336928-A1 | Heterocyclic Compounds And Methods Of Use Thereof | GRIN2C, COMT, NLN | OPRM1 259/4885OPRL1 771/4885OPRK1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.